OmniAb reports Q4 EPS (14c), consensus (15c)

Reports Q4 revenue $4.8M, consensus $7.5M. “2023 was a year of significant expansion of OmniAb’s partnership base and pipeline programs as we continued to execute against our plan, while key partner programs made significant progress despite last year’s sector-related headwinds. Partners exceeded our expectations regarding the number of new programs entering the clinic, with a total of six new entrants last year,” said Matt Foehr, Chief Executive Officer of OmniAb. “In addition, we successfully launched two new technologies and expanded our business development function, now with a presence in the U.S., EU and Asia Pacific. We look forward to meaningful advancements in 2024 and in the coming years, as we are now staffed and resourced to efficiently leverage the future growth of the business.”